Forest Labs Aims To Launch Once-Daily Namenda Ahead Of Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Alzheimer's line-extension is in Phase III, and first ANDA with paragraph IV certification for current twice-daily formula could be filed next fall.
You may also be interested in...
Pfizer/Eisai’s Aricept Becomes First Treatment Approved For All Degrees of Alzheimer’s
Because Aricept is often used in combination with Namenda, though, Forest says it is not concerned about market share erosion.
Lexapro Scripts Hold Up Against Competition From Generic Zoloft
Forest's antidepressant shows prescription growth in September, despite August entry of generic Zoloft.
Nebivolol Approval Could Come In Mid-2007, Forest Says
The firm is conducting small studies of short duration after meeting with FDA regarding a May 2005 “approvable” letter.